Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 4/20 | 0.58 |
| ▸ | AGPAT2 | O15120 | 7/20 | 0.43 |
| ▸ | JAK2 | O60674 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | F7 | P08709 | 1/20 | 0.37 |
| ▸ | F3 | P13726 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24521445 | 0.81 | MEN1 (0.39) | IDO1JAK2AR | |
| SCHEMBL11624239 | 0.81 | IDO1 (0.56) | IDO1AGPAT2F7F3DYRK1A | |
| SCHEMBL13963717 | 0.79 | NISCH (0.45) | IDO1AGPAT2CYP3A4AR | |
| SCHEMBL29785807 | 0.79 | PLA2G7 (0.42) | IDO1CYP3A4DYRK1APOLB | |
| SCHEMBL31039366 | 0.79 | IDO1 (0.38) | IDO1F7F3DYRK1A | |
| SCHEMBL14400038 | 0.79 | IDO1 (0.58) | IDO1CYP3A4F7F3DYRK1A | |
| SCHEMBL6031031 | 0.79 | IDO1 (0.58) | IDO1AGPAT2 | |
| SCHEMBL14371098 | 0.78 | ALDH1A1 (0.41) | IDO1F7F3DYRK1APOLB | |
| SCHEMBL3846339 | 0.78 | ALPL (0.49) | IDO1F7F3DYRK1A | |
| SCHEMBL22810391 | 0.76 | IDO1 (0.37) | IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013096630-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | WO | disclosed |